Anti-Müllerian hormone as a marker of ovarian reserve: An update

Women's Health

Volumn 4, Issue 2, 2008, Pages 137-141

  Robertson, David M ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Anti M llerian; Antral follicle count; Follicle stimulating hormone; Hormone; Inhibin B; IVF; Polycystic ovarian syndrome; Premature ovarian failure

Indexed keywords

ANDROGEN; AROMATASE; BIOLOGICAL MARKER; ESTRADIOL; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR;

BIOLOGICAL MONITORING; BIOPSY TECHNIQUE; CELL COUNT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ELDERLY CARE; ENZYME ACTIVITY; FERTILIZATION IN VITRO; GONADAL DISEASE; GRANULOSA CELL; GRANULOSA CELL TUMOR; HODGKIN DISEASE; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; INFERTILITY THERAPY; MENOPAUSE; OBESITY; OOCYTE; OVARY FOLLICLE CELL; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PREDICTION; PREMATURE OVARIAN FAILURE; RELIABILITY; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; FERTILIZATION IN VITRO; HUMANS; OOCYTES; OVARIAN FUNCTION TESTS; OVARY; POLYCYSTIC OVARY SYNDROME;

EID: 41949137986     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.2.137     Document Type: Review

References (42)

1. Seifer DB, Maclaughlin DT: Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil. Steril. 88, 539-546 (2007).
2. Visser JA, de Jong FH, Laven JS, Themmen AP: Anti-Mollerian hormone: a new marker for ovarian function. Reproduction 131, 1-9 (2006).
3. Visser JA, Themmen APN: Anti-Mullerian hormone and folliculogenesis. Mol. Cell Endocrinol. 234, 81-86 (2005).
4. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP, Hovatta O: Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum. Reprod. 21, 2223-2237 (2006).
5. Stubbs SA, Stark J, Dilworth SM, Franks S, Harjy K: Abnormal preantral folliculogenesis in polycystic ovaries is associated with increased granulosa cell division. J. Clin, Endocrinol. Metab. 92, 4418-4426 (2007).
6. Webber LJ, Stubbs SA, Stark J et al.: Prolonged survival in culture of preantral follicles from polycystic ovaries. J. Clin. Endocrinol. Metab. 92, 1975-1978 (2007).
7. Wachs DS, Coffier MS, Malcom PJ, Chang RJ: Serum anti-mullerian hormone concentrations are not altered by acute administration of follicle stimulating hormone in polycystic ovary syndrome and normal women. J. Clin. Endocrinol. Metab. 92, 1871-1874 (2007).
8. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy Ch, Englert Y: Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 22, 1837-1840 (2007).
9. La Marca A, Stabile G, Artenisio AC, Volpe A: Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum. Reprod. 21, 3103-3107 (2006).
10. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ: Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin. Endocrinol. Metab 91, 4057-4063 (2006).
11. Stubbs SA, Hardy K, Da Silva-Buttkus P et al.: Anti-müllerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J. Clin. Endocrinol. Metab. 90, 5536-5543 (2005).
12. Meduri G, Massin N, Guibourdenche J et al.: Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum. Reprod. 22, 117-123 (2007).
13. Andersen CY, Byskov AG: Estradiol and regulation of anti-Mullerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles fluid. J. Clin. Endocrinol Metab. 91, 4064-4069 (2006).
14. Pellatt L, Hanna L, Brincat M et al.: Granulosa cell production of anti-Mullerian hormone is increased in polycystic ovaries. J. Clin, Endocrinol. Metab. 92, 240-245 (2007).
15. Andersen CY, Lossi K: Increased intrafollicular androgen levels affect human granulosa cell secretion of anti-mullerian hormone and inhibin-B. Fertil. Steril. (2007) (Epub ahead of print).
16. McIiveen M, Skull JD, Ledger WL: Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum. Reprod. 22, 778-785 (2007),
17. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD: Antimullerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil. Steril. 87, 223-236 (2007).
18. Broekmans FJ, Kwee J, Hendriks DJ, Moi BW, Lambalk CB: A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update 12, 685-718 (2006).
19. Johnson NP, Bagrie EM, Coomarasamy A et al.: Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG 113, 1472-1480 (2006).
20. Nelson SM, Yates RW, Fleming R: Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy. Hum. Reprod. 22, 2414-2421 (2007).
21. La Marca A, Giulini S, Tirelli A et al.: Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum. Reprod. 22, 766-771 (2007).
22. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G: Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum. Reprod. 21, 2022-2026 (2006).
23. Fanchin R, Mendez Lozano DH, Frydman N et al.: Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J. Clin. Endocrinol. Metab. 92, 1796-1802 (2007).
24. La Marca A, Giulini S, Tirelli A et al.: Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum. Reprod. 22, 766-771 (2007).
25. Nardo LG, Christodoulou D, Gould D, Roberts SA, Fitzgerald CT, Laing I: Anti-Mullerian hormone levels and antral follicle count in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecol. Endocrinol. (2007) (Epub ahead of print).
26. Pigny P, Jonard S, Robert Y, Dewailly D: Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 941-945 (2006).
27. Wang J G, Nakhuda GS, Guarnaccia MM, Sauer MV, Lobo RA: Mullerian inhibiting substance and disrupted folliculogenesis in polycystic ovary syndrome. Am. J. Obstet. Gynecol. 196(1)77, E1-E5 (2007).
28. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47 (2004).
29. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA: Elevated serum mullerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. Fertil. Steril. 85, 1541-1543 (2006).
30. Codner E, Iñiguez G, Villaroel C et al.: Hormonal profile in women with polycystic ovarian syndrome with or without Type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. (2007) (Epub ahead of print).
31. Eidar-Geva T, Margatioth EJ, Gal M et al.: Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum. Reprod. 20, 1814-1819 (2005).
32. Catteau-Jonard S, Pigny P, Reyss AC, Decanter C, Poncelet E, Dewailly D: Changes in serum anti-Mullerian hormone level during low-dose recombinant follicular stimulating hormone therapy for anovulation in polycystic ovary syndrome. J Clin. Endocrinol. Metab. 92, 4138-4143 (2007).
33. Crisosto N, Codner E, Maliqueo M et al.: Anti-Mullerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J. Clin, Endocrinol. Metab. 92, 2739-2743 (2007).
34. Sir-Petermann T, Codner E, Maliqueo M et al.: Increased anti-Mullerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 3105-319 (2006).
35. Moran LJ, Noakes M, Clifton PM, Norman RJ: The use of anti-Mullerian hormone in predicting menstrual response following weight loss in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 3796-3802 (2007).
36. Yeh J, Min B, Peresie J, Liang YJ, Arroyo A: Serum and ovarian Mullerian inhibiting substance, and their decline in reproductive aging. Fertil. Steril. 87, 1227-1230 (2007).
37. Freeman EW. Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd: Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil. Steril. 87, 101-106 (2007).
38. La Marca A, Pati M, Orvieto R, Stabile G, Carducci Artenisio A, Volpe A: Serum anti-müllerian hormone levels in women with secondary amenorrhea. Fertil. Steril. 85, 1547-1549 (2006).
39. van Beek RD, van den Heuvel-Eibrink MM, Laven JS et al.: Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J. Clin. Endocrinol. Metab. 92, 3869-3874 (2007).
40. Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L: Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematotogy 12, 141-147 (2007).
41. La Marca A, Volpe A: The anti-Mullerian hormone and ovarian cancer. Hum. Reprod. Update 13, 265-273 (2007).
42. Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT, Donahoe PK: Müllerian inhibiting substance in the diagnosis and management of intersex and gonadal abnormalities. J. Mediatr. Surg. 28, 439-444 (1993).